Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefitfrom anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’

Andrew Rowland; Mafalda Dias; Michael Wiese; Ganessan Kichenadasse; Ross McKinnon; Christos Karapetis; Michael Sorich

doi:10.1038/bjc.2015.325

Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefitfrom anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’

Research output: Contribution to journal › Letter › peer-review

8 Citations (Scopus)

Original language	English
Pages (from-to)	1635
Number of pages	1
Journal	British Journal of Cancer
Volume	113
Issue number	11
DOIs	https://doi.org/10.1038/bjc.2015.325
Publication status	Published - 1 Dec 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/bjc.2015.325

Cite this

@article{56f0f5b669d447a482a3faf86b7b6f1d,

title = "Reply: Comment on {\textquoteleft}Meta-analysis of BRAF mutation as a predictive biomarker of benefitfrom anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer{\textquoteright}",

author = "Andrew Rowland and Mafalda Dias and Michael Wiese and Ganessan Kichenadasse and Ross McKinnon and Christos Karapetis and Michael Sorich",

year = "2015",

month = dec,

day = "1",

doi = "10.1038/bjc.2015.325",

language = "English",

volume = "113",

pages = "1635",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "11",

}

Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefitfrom anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’. / Rowland, Andrew; Dias, Mafalda; Wiese, Michael et al.
In: British Journal of Cancer, Vol. 113, No. 11, 01.12.2015, p. 1635.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefitfrom anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’

AU - Rowland, Andrew

AU - Dias, Mafalda

AU - Wiese, Michael

AU - Kichenadasse, Ganessan

AU - McKinnon, Ross

AU - Karapetis, Christos

AU - Sorich, Michael

PY - 2015/12/1

Y1 - 2015/12/1

UR - https://www.scopus.com/pages/publications/84949319246

U2 - 10.1038/bjc.2015.325

DO - 10.1038/bjc.2015.325

M3 - Letter

SN - 0007-0920

VL - 113

SP - 1635

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 11

ER -

Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefitfrom anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’

UN SDGs

Access to Document

Other files and links

Cite this